WO2017159592A1 - 肥満リスクの診断キット,及び肥満の発症リスクの分析方法 - Google Patents
肥満リスクの診断キット,及び肥満の発症リスクの分析方法 Download PDFInfo
- Publication number
- WO2017159592A1 WO2017159592A1 PCT/JP2017/009903 JP2017009903W WO2017159592A1 WO 2017159592 A1 WO2017159592 A1 WO 2017159592A1 JP 2017009903 W JP2017009903 W JP 2017009903W WO 2017159592 A1 WO2017159592 A1 WO 2017159592A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- obesity
- risk
- gene
- expression level
- synoviolin gene
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
Definitions
- the present invention relates to a diagnostic kit for obesity risk and a method for analyzing the risk of developing obesity.
- Japanese Patent No. 5279492 discloses a probe for use in polymorphism analysis of obesity genes. By analyzing the obesity gene in this way, a technique for analyzing a genetic risk that a subject develops obesity has been developed.
- the present invention provides a diagnostic kit for obesity risk and a method for analyzing the risk of developing obesity.
- the present invention is basically based on the knowledge obtained by the Examples that the genetic information of those who are obese and those who are not obese is analyzed, and those who are obese express a large amount of synoviolin gene.
- the expression level of the Synoviolin gene in those who are obese is statistically significant and higher than the expression level of the Synoviolin gene in those who are not.
- the Synoviolin gene is considered to be an obesity marker for judging the risk (possibility of morbidity) of whether or not there is a high tendency to genetically become obese.
- the first aspect of the present invention relates to a diagnostic kit for obesity risk.
- This diagnostic kit for obesity risk includes a probe for identifying the Synoviolin gene, which is an obesity marker.
- the second aspect of the present invention relates to a method for analyzing the risk of developing obesity.
- This method includes a step of measuring the expression level of a synoviolin gene in a sample collected from a target organism, and a step of determining the risk of developing obesity using the expression level of the synoviolin gene.
- the present invention can provide a diagnostic kit for obesity risk and a method for analyzing the risk of developing obesity.
- FIG. 1 is a box and whisker plot showing the expression levels of Synoviolin gene and ATF6 gene.
- FIG. 2 is a box plot showing the expression levels of the XBP1 gene and the EIF2 gene.
- FIG. 3 is a box plot showing the expression levels of the GRP78 gene and the IREI1 gene.
- the first aspect of the present invention relates to a diagnostic kit for obesity risk.
- This diagnostic kit collects a sample (for example, blood, saliva, nails, hair) from a target organism (for example, a human) and measures the expression level of the synoviolin gene contained in the collected sample.
- a target organism for example, a human
- this diagnostic kit for risk of obesity includes a probe for identifying the Synoviolin gene that is an obesity marker. By using this probe, the expression level of the synoviolin gene can be determined.
- This diagnostic kit can be used for genetic diagnosis, for example, to determine whether or not it has a gene prone to obesity.
- the diagnostic kit may contain a known element for measuring the expression level of the target synoviolin gene in addition to the probe. Examples of such elements are primers used in PCR and may include a PCR measurement device.
- a known method may be appropriately employed.
- An example of a method for determining the expression level of the synoviolin gene is PCR.
- the expression level of the synoviolin gene for example, the expression level at the mRNA level may be measured, or the expression level at the protein level may be measured.
- methods for determining the expression level of the Synoviolin gene are Northern blotting, quantitative RT-PCR, Western blotting, ELISA, and immunostaining. Since these methods are known and kits for realizing these methods are sold, the expression level of the synoviolin gene can be determined in consideration of the instruction manual for the kits.
- Probes for identifying the Synoviolin gene are known.
- An example of a probe for identifying the Synoviolin gene is No. 16 in the Roche universal probe library.
- the region amplified by this probe is that of SEQ ID NO: 1.
- the obesity risk diagnostic kit of the present invention may appropriately include known elements for genetic diagnosis in addition to the above-described probes.
- the second aspect of the present invention relates to a method for analyzing the risk of developing obesity.
- This method includes a step of measuring the expression level of a synoviolin gene in a sample collected from a target organism, and a step of determining the risk of developing obesity using the expression level of the synoviolin gene.
- the step of measuring the expression level of the synoviolin gene is as described above.
- it may be compared with the expression level of the synoviolin gene in a sample collected from a healthy subject.
- a threshold value regarding the expression level of the synoviolin gene may be obtained in advance using a sample of a plurality of obese or non-obese subjects and compared with the threshold.
- This method for analyzing the risk of developing obesity may be automatically obtained using a computer.
- the computer has an input / output unit, a calculation unit, a control unit, and a storage unit, which can exchange information using a bus or the like.
- storage part has memorize
- a control part reads the calculation program memorize
- the obtained analysis result is appropriately sent to and stored in the storage unit by the control unit and is output from the input / output unit. In this way, the risk of developing obesity in the subject is required.
- RNA recovery and real-time (RT) -PCR Blood was collected from 33 healthy individuals, and lymphocytes were collected using Ficoll separation method. Using the collected lymphocytes, total RNA was generated using ISOGEN (manufactured by Nippon Gene Co., Ltd.). Table 1 shows information on the age, sex, height, and BMI value of healthy persons (healthy donors) in the examples.
- SYVN1 (Synoviolin gene) Forward primer: 5'- ccagtacctcaccgtgctg-3 (SEQ ID NO: 2) Reverse primer: 5'-tctgagctagggatgctggt-3 '(SEQ ID NO: 3)
- the probe used was No. 16 from the Roche universal probe library.
- ATF6 Forward primer: 5′-gcagaaggggagacacattt-3 ′ (SEQ ID NO: 4)
- Reverse primer 5'-tgtggtcttgttatgggtggt-3 ', (SEQ ID NO: 5)
- the probe used was No. 62 from the Roche universal probe library.
- XBP1 Forward primer: 5'-ggagttaagacagcgcttgg-3 '(SEQ ID NO: 6) Reverse primer: 5'-cactggcctcacttcattcc-3 ', (SEQ ID NO: 7)
- SEQ ID NO: 7 As a probe, No. 37 of the universal probe library of Roche was used.
- IRE1 Forward primer: 5'-gaagcatgtgctcaaacacc-3 '(SEQ ID NO: 8)
- Reverse primer 5'-tctgtcgctcacgtcctg-3 ', (SEQ ID NO: 9)
- SEQ ID NO: 9 As a probe, No. 502 of the universal probe library of Roche Corporation was used.
- eIF2a Forward primer: 5'-gaagctaagaaagctgcaaagc-3 '(SEQ ID NO: 10)
- Reverse primer 5'- cagtgtttcgtggtgtgctc-3 ', (SEQ ID NO: 11)
- the probe used was No. 43 from the Roche universal probe library.
- GRP78 Forward primer: 5'-catcaagttcttgccgttca-3 '(SEQ ID NO: 12) Reverse primer: 5'-ttcaggagcaaatgtctttgttt-3 ', (SEQ ID NO: 13)
- the probe used was No. 10 from the Roche universal probe library.
- RPLPO Forward primer: 5′-gcagaaggggagacacattt-3 ′ (SEQ ID NO: 14)
- Reverse primer 5′-tgtggtcttgttatgggtggt-3 ′, (SEQ ID NO: 15)
- the probe used was No. 62 from the Roche universal probe library.
- RT-PCR For RT-PCR, ReverseTra Ace (registered trademark), which is a highly efficient reverse transcriptase manufactured by Toyobo Co., Ltd., was used.
- the conditions for RT-PCR were as follows. RT-PCR determined conditions such as temperature setting based on the instruction manual of the kit used. 1 ⁇ g of total RNA and RNase-free water were combined to make 10 ⁇ L, incubated at 65 ° C. for 5 minutes, and then cooled on ice for 5 minutes.
- the obtained expression level was subjected to statistical analysis using Excel statistical software 2012 (the Excel Statistical software 2012) manufactured by SSRI Japan.
- the RNA expression level of each gene was divided into a body BMI (body mass index) of 25 kg / m 2 or more and the following, and statistically significant differences were verified by unpaired Student's t-test. . At that time, if the p-value was 0.05 or less, it was judged that there was a statistically significant difference.
- FIG. 1 to 3 are box and whisker plots showing the expression level of each RNA.
- FIG. 1 is a box and whisker plot showing the expression levels of Synoviolin gene and ATF6 gene.
- FIG. 2 is a box plot showing the expression levels of the XBP1 gene and the EIF2 gene.
- FIG. 3 is a box plot showing the expression levels of the GRP78 gene and the IREI1 gene.
- the present invention can be used in the field of genetic diagnostic equipment and in the diagnostic business.
- Sequence number 2 Primer Sequence number 3: Primer Sequence number 4: Primer Sequence number 5: Primer Sequence number 6: Primer Sequence number 7: Primer Sequence number 8: Primer Sequence number 9: Primer Sequence number 10: Primer Sequence number 11: Primer Sequence number 12: Primer Sequence number 13: Primer Sequence number 14: Primer Sequence number 15: Primer
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
配列番号1:
ccagtacctcaccgtgctggcctccttggggcccccccggcctgccacttcagtcaactccactgaggagactgccactacagttgttgctgctgcctcctccaccagcatccctagctcaga
33人の健常人から採血し,フィコール分離法を用いて,リンパ球を回収した。回収したリンパ球を用い,ISOGEN(株式会社ニッポンジーン製)を用いて,トータルRNAを生成した。表1に実施例における健常人(ヘルシードナー)の年齢や性別,身長,BMI値に関する情報を示す。
フォワードプライマー:5′- ccagtacctcaccgtgctg -3(配列番号2)
リバースプライマー:5′- tctgagctagggatgctggt -3′(配列番号3)
プローブとして,ロッシュ社のユニバーサルブローブライブラリーの16番を用いた。
フォワードプライマー:5′- gcagaaggggagacacattt -3′(配列番号4)
リバースプライマー:5′- tgtggtcttgttatgggtggt -3′, (配列番号5)
プローブとして,ロッシュ社のユニバーサルブローブライブラリーの62番を用いた。
フォワードプライマー:5′- ggagttaagacagcgcttgg -3′(配列番号6)
リバースプライマー:5′- cactggcctcacttcattcc -3′, (配列番号7)
プローブとして,ロッシュ社のユニバーサルブローブライブラリーの37番を用いた。
フォワードプライマー:5′- gaagcatgtgctcaaacacc -3′(配列番号8)
リバースプライマー:5′- tctgtcgctcacgtcctg -3′, (配列番号9)
プローブとして,ロッシュ社のユニバーサルブローブライブラリーの502番を用いた。
フォワードプライマー:5′- gaagctaagaaagctgcaaagc -3′(配列番号10)
リバースプライマー:5′- cagtgtttcgtggtgtgctc -3′, (配列番号11)
プローブとして,ロッシュ社のユニバーサルブローブライブラリーの43番を用いた。
フォワードプライマー:5′- catcaagttcttgccgttca -3′(配列番号12)
リバースプライマー:5′- ttcaggagcaaatgtctttgttt -3′, (配列番号13)
プローブとして,ロッシュ社のユニバーサルブローブライブラリーの10番を用いた。
フォワードプライマー:5′- gcagaaggggagacacattt -3′(配列番号14)
リバースプライマー:5′- tgtggtcttgttatgggtggt -3′, (配列番号15)
プローブとして,ロッシュ社のユニバーサルブローブライブラリーの62番を用いた。
RT-PCRの条件は以下の通りであった。RT-PCRは,用いたキットの使用説明書に基づいて温度設定等の条件を定めた。
全RNA 1μgと,RNaseフリー水を合わせて10μLとし,65℃で5分インキュベートした後,氷上で5分冷却した。
5×バッファ 4μL
10mM dNTPs ミクスチャ 2μL
ReverTra Ace(R) 1μL
RNase 阻害剤 0.5μL
ランダムプライマー (25ピコモル/μL) 1μL
RNaseフリー水 1.5μL
RNA溶液 10μL
合計 20μL
配列番号3:プライマー
配列番号4:プライマー
配列番号5:プライマー
配列番号6:プライマー
配列番号7:プライマー
配列番号8:プライマー
配列番号9:プライマー
配列番号10:プライマー
配列番号11:プライマー
配列番号12:プライマー
配列番号13:プライマー
配列番号14:プライマー
配列番号15:プライマー
Claims (2)
- 肥満マーカーであるシノビオリン遺伝子を同定するためのプローブを含む,肥満リスクの診断キット。
- 対象となる生物から採取された試料におけるシノビオリン遺伝子の発現量を測定する工程と,
前記シノビオリン遺伝子の発現量を用いて,肥満の発症リスクを求める工程を含む,
肥満の発症リスクの分析方法。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3014526A CA3014526A1 (en) | 2016-03-15 | 2017-03-13 | Obesity risk diagnosis kit and method for analyzing risk of obesity onset |
SG11201806907XA SG11201806907XA (en) | 2016-03-15 | 2017-03-13 | Obesity risk diagnosis kit and method for analyzing risk of obesity onset |
EP17766592.4A EP3431594A1 (en) | 2016-03-15 | 2017-03-13 | Obesity risk diagnosis kit and method for analyzing risk of obesity onset |
US16/084,969 US20190078074A1 (en) | 2016-03-15 | 2017-03-13 | Obesity risk diagnosis kit and method for analyzing risk of obesity onset |
JP2018505907A JPWO2017159592A1 (ja) | 2016-03-15 | 2017-03-13 | 肥満リスクの診断キット,及び肥満の発症リスクの分析方法 |
CN201780017278.1A CN108779454A (zh) | 2016-03-15 | 2017-03-13 | 肥胖风险的诊断试剂盒和肥胖发病风险的分析方法 |
AU2017234903A AU2017234903A1 (en) | 2016-03-15 | 2017-03-13 | Obesity risk diagnosis kit and method for analyzing risk of obesity onset |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016-051038 | 2016-03-15 | ||
JP2016051038 | 2016-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017159592A1 true WO2017159592A1 (ja) | 2017-09-21 |
Family
ID=59851484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/009903 WO2017159592A1 (ja) | 2016-03-15 | 2017-03-13 | 肥満リスクの診断キット,及び肥満の発症リスクの分析方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20190078074A1 (ja) |
EP (1) | EP3431594A1 (ja) |
JP (1) | JPWO2017159592A1 (ja) |
CN (1) | CN108779454A (ja) |
AU (1) | AU2017234903A1 (ja) |
CA (1) | CA3014526A1 (ja) |
SG (1) | SG11201806907XA (ja) |
WO (1) | WO2017159592A1 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005012570A1 (ja) * | 2003-07-31 | 2005-02-10 | Banyu Pharmaceutical Co., Ltd. | Slc25a10による肥満治療に有効な化合物の評価方法 |
WO2010131704A1 (ja) * | 2009-05-13 | 2010-11-18 | 塩野義製薬株式会社 | 内臓脂肪型肥満の検査薬およびその利用 |
WO2011149057A1 (ja) * | 2010-05-27 | 2011-12-01 | 国立大学法人 東京大学 | 肥満化リスク・糖尿病発症リスクの検出方法 |
WO2014103863A1 (ja) * | 2012-12-26 | 2014-07-03 | Nakajima Toshihiro | 肥満症の予防及び治療作用を有する化合物のスクリーニング方法 |
-
2017
- 2017-03-13 AU AU2017234903A patent/AU2017234903A1/en not_active Abandoned
- 2017-03-13 WO PCT/JP2017/009903 patent/WO2017159592A1/ja active Application Filing
- 2017-03-13 US US16/084,969 patent/US20190078074A1/en not_active Abandoned
- 2017-03-13 SG SG11201806907XA patent/SG11201806907XA/en unknown
- 2017-03-13 CN CN201780017278.1A patent/CN108779454A/zh active Pending
- 2017-03-13 CA CA3014526A patent/CA3014526A1/en not_active Abandoned
- 2017-03-13 JP JP2018505907A patent/JPWO2017159592A1/ja active Pending
- 2017-03-13 EP EP17766592.4A patent/EP3431594A1/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005012570A1 (ja) * | 2003-07-31 | 2005-02-10 | Banyu Pharmaceutical Co., Ltd. | Slc25a10による肥満治療に有効な化合物の評価方法 |
WO2010131704A1 (ja) * | 2009-05-13 | 2010-11-18 | 塩野義製薬株式会社 | 内臓脂肪型肥満の検査薬およびその利用 |
WO2011149057A1 (ja) * | 2010-05-27 | 2011-12-01 | 国立大学法人 東京大学 | 肥満化リスク・糖尿病発症リスクの検出方法 |
WO2014103863A1 (ja) * | 2012-12-26 | 2014-07-03 | Nakajima Toshihiro | 肥満症の予防及び治療作用を有する化合物のスクリーニング方法 |
Also Published As
Publication number | Publication date |
---|---|
US20190078074A1 (en) | 2019-03-14 |
EP3431594A1 (en) | 2019-01-23 |
CA3014526A1 (en) | 2017-09-21 |
SG11201806907XA (en) | 2018-09-27 |
AU2017234903A1 (en) | 2018-08-30 |
JPWO2017159592A1 (ja) | 2019-03-28 |
CN108779454A (zh) | 2018-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6577005B2 (ja) | 生体サンプルにおける定量的細胞組成を特定する方法 | |
Zhang et al. | Comprehensive one-step molecular analyses of mitochondrial genome by massively parallel sequencing | |
EP2584050B1 (en) | Diagnostic biomarkers of diabetes | |
JP7241352B2 (ja) | 肺扁平上皮癌のサブタイピングのための方法 | |
Kwong et al. | The importance of analysis of long-range rearrangement of BRCA1 and BRCA2 in genetic diagnosis of familial breast cancer | |
JP6931125B2 (ja) | 標的遺伝子発現の数学的モデル化を使用する、jak−stat1/2細胞シグナル伝達経路活性の評価 | |
US20190367984A1 (en) | Methods for predicting response to anti-tnf therapy | |
RU2737449C1 (ru) | Система для предсказания прогноза и пользы от вспомогательной химиотерапии для больных раком желудка ii и iii стадии | |
EP3332031B1 (en) | Snp rs12603226 as a predictive marker for nafld | |
Srettabunjong et al. | The study on telomere length for age estimation in a Thai population | |
JP2022048190A (ja) | ドライアイ疾患の予後のための遺伝子シグネチャー | |
JP6585175B2 (ja) | クローン病のバイオマーカーとしての宿主dna | |
KR20180007291A (ko) | 암 리스크를 검출하는 방법 | |
US20180187261A1 (en) | Kit and method for the diagnosis/prognosis of idiopathic scoliosis | |
US11127486B2 (en) | Systems and methods for predicting a smoking status of an individual | |
RU2017132275A (ru) | Способ измерения изменения в иммунном репертуаре индивидуума | |
WO2017159592A1 (ja) | 肥満リスクの診断キット,及び肥満の発症リスクの分析方法 | |
Tsai et al. | A probe-based qRT-PCR method to profile immunological gene expression in blood of captive beluga whales (Delphinapterus leucas) | |
JP2023157965A (ja) | アトピー性皮膚炎の検出方法 | |
JP2021180654A (ja) | パーキンソン病の検出方法 | |
Yüksel et al. | Is there an association between two-STAT4 gene polymorphisms and rheumatoid arthritis in turkish population? | |
Puncevičienė | Associations of rheumatoid arthritis etiopathogenesis and clinical course with genetic and epigenetic factors | |
Azmy et al. | UL 16 Binding Protein 3 Gene Expression: Does It Have an Association With Alopecia Areata? | |
Miyoshi et al. | Exploration of reference genes for the development of a diagnostic kit on vascular aging in human saliva | |
KR20200002237A (ko) | 비만 진단을 위한 마이크로RNA let-7a 또는 let-7f 바이오마커 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2018505907 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3014526 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2017234903 Country of ref document: AU Date of ref document: 20170313 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017766592 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017766592 Country of ref document: EP Effective date: 20181015 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17766592 Country of ref document: EP Kind code of ref document: A1 |